Skip to main content
OpenTrials
Completed

NCT Number: NCT04345419

Remdesivir Efficacy in Coronavirus Disease

COVID 19 treatment using Remedesvir.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Tanta university hospital, Assuit University, Ainshams University

Tanta, Egypt

About this study

COVID 19 treatment using Remedesvir. Is this drug effective?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COVID 19 patients

Exclusion criteria

  • allergy or contraindication to the drug

Treatment and study plan

Remdesivir

Drug

Remdesivir as antiviral drug

Standard of Care Treatment

Other

Standard of care treatment

Primary outcomes

  1. Number of patients with improvement or mortality

    Time frame: 6 months

    the estimated number of patients with improvement or mortality

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Remdesivir in COVID-19 Treatment: A Randomised Trial

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 14, 2020
Registry last updated
Aug 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.